Genetic Signatures (ASX:GSS) ROCE % : -57.88% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genetic Signatures's annualized ROCE % for the quarter that ended in Dec. 2023 was -57.88%.

Genetic Signatures ROCE % Historical Data

The historical data trend for Genetic Signatures's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures ROCE % Chart

Genetic Signatures Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-29.09

-7.21

3.74

5.91

-28.72

Genetic Signatures Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial													17.73	-5.63	-26.43	-31.16	-57.88

Genetic Signatures ROCE % Calculation

Genetic Signatures's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-14.051	/	( ( (59.654 - 4.805)	+	(49.078 - 6.069) )	/ 2 )
	=	-14.051	/	( (54.849	+	43.009)	/ 2 )
	=	-14.051	/	48.929
	=	-28.72 %

Genetic Signatures's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-24.202	/	( ( (49.078 - 6.069)	+	(44.455 - 3.83) )	/ 2 )
	=	-24.202	/	( ( 43.009	+	40.625 )	/ 2 )
	=	-24.202	/	41.817
	=	-57.88 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Genetic Signatures (ASX:GSS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genetic Signatures ROCE % Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetic Signatures (ASX:GSS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042

Website

https://www.geneticsignatures.com

Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.